[{"address1": "900 North Point Parkway", "address2": "Suite 200", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "678 270 3631", "fax": "678 270 4033", "website": "https://clearsidebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.", "age": 71, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 836154, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles A. Deignan", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 568676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas A. Ciulla M.B.A., M.D.", "age": 58, "title": "Chairman of Scientific Advisory Board", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 531517, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Kobin", "age": 56, "title": "Head of Investor Relations", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick  McElheny", "title": "Senior Vice President of Corporate Development & Alliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rafael V. Andino", "age": 58, "title": "Senior Vice President of Engineering & Manufacturing", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan L. Coultas Ph.D.", "title": "Chief Clinical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Hang  Chong M.B.A., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leslie B. Zacks", "age": 54, "title": "Secretary", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.25, "open": 1.24, "dayLow": 1.21, "dayHigh": 1.265, "regularMarketPreviousClose": 1.25, "regularMarketOpen": 1.24, "regularMarketDayLow": 1.21, "regularMarketDayHigh": 1.265, "forwardPE": -2.1964285, "volume": 109173, "regularMarketVolume": 109173, "averageVolume": 381755, "averageVolume10days": 152830, "averageDailyVolume10Day": 152830, "bid": 1.18, "ask": 1.26, "bidSize": 100, "askSize": 100, "marketCap": 91919256, "fiftyTwoWeekLow": 0.65, "fiftyTwoWeekHigh": 2.12, "priceToSalesTrailing12Months": 10.875444, "fiftyDayAverage": 1.4376, "twoHundredDayAverage": 1.15333, "currency": "USD", "enterpriseValue": 94955472, "floatShares": 64642176, "sharesOutstanding": 74731104, "sharesShort": 338681, "sharesShortPriorMonth": 224267, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0045, "heldPercentInsiders": 0.07455, "heldPercentInstitutions": 0.25304002, "shortRatio": 1.28, "shortPercentOfFloat": 0.0047999998, "impliedSharesOutstanding": 74731104, "bookValue": -0.312, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -34968000, "trailingEps": -0.55, "forwardEps": -0.56, "enterpriseToRevenue": 11.235, "enterpriseToEbitda": -3.741, "52WeekChange": 0.18269229, "SandP52WeekChange": 0.2704494, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CLSD", "underlyingSymbol": "CLSD", "shortName": "Clearside Biomedical, Inc.", "longName": "Clearside Biomedical, Inc.", "firstTradeDateEpochUtc": 1464874200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea57bdfa-5d41-3e30-b431-13e72798980d", "messageBoardId": "finmb_145617165", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.23, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.5, "targetMedianPrice": 5.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 35355000, "totalCashPerShare": 0.506, "ebitda": -25379250, "totalDebt": 44391000, "totalRevenue": 8452000, "revenuePerShare": 0.132, "returnOnAssets": -0.37495, "revenueGrowth": 56.5, "grossMargins": 0.958, "operatingMargins": -35.6913, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-14"}]